A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TCN-032 (HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE M2 PROTEIN OF INFLUENZA A VIRUS) IN SUBJECTS CHALLENGED WITH H3N2 INFLUENZA A VIRUS.

Trial Profile

A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TCN-032 (HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE M2 PROTEIN OF INFLUENZA A VIRUS) IN SUBJECTS CHALLENGED WITH H3N2 INFLUENZA A VIRUS.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs TCN 032 (Primary)
  • Indications Influenza A virus infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Theraclone Sciences
  • Most Recent Events

    • 08 Sep 2013 Primary endpoint 'Symptoms' has not been met.
    • 01 Aug 2013 Status changed from recruiting to completed, according to a Theraclone Sciences media release. Results are expected to be announced later in 2013.
    • 25 Oct 2012 Trial initiation announced in a Theraclone Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top